



DEPARTMENT OF HEALTH AND HUMAN SERVICES

m 3546n  
Food and Drug Administration  
Cincinnati District Office  
6751 Steger Drive  
Cincinnati, OH 45237-3097  
Telephone: (513) 679-2700  
FAX: (513) 679-2772

*Amended*  
**WARNING LETTER**

Cin WL -1635-0

February 22, 2000

**CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

Ms. Judith DeRocchis  
Director of Radiology  
Belmont Community Hospital  
4697 Harrison St.  
Bellaire, OH 43906

Facility I.D.#: 213215 (Belmont  
Professional Center)

Dear Ms. DeRocchis:

This is an amended letter to the Warning Letter dated February 2, 2000 that was mailed to you. The amendment of the Warning Letter is to update the results of the January 27, 2000 inspection. Your facility was allowed up to five working days to provide to the inspector the "Claimed Documents." Unfortunately your facility was unable to provide the appropriate document to demonstrate that your facility was in compliance with Quality Standards for Mammography (Standards) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12 upto the date of the inspection. . Also this document is to make note that your facility was incorrectly cited for quality control deficiencies that occurred prior to April 28, 1999 which is the effective date of the permanent regulations to the Mammography Quality Standards Act. Please note the shaded portions in this letter that represent the amended text.

A representative from the State of Ohio radiation control program under contract to the Food and Drug Administration inspected **Belmont Professional Center, 51339 National Road East, St. Clairsville, OH 43950** on January 27, 2000. This inspection revealed that your facility failed to comply with the Quality Standards for Mammography (Standards) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12, as follows:

1. Your facility conducted mammography on at least 23 patients in the time period of January 10 through January 25, 2000 without a valid FDA certificate. Your FDA certificate expired on January 8, 2000.

The Mammography Quality Standards Act of 1992 (MQSA), under 42 U.S.C. 263b(b)(1)(A)), provides that no facility may conduct examinations or procedures involving mammography after October 1, 1994, unless the facility has a valid certificate.

2. The inspection revealed that your facility processed mammograms when the processor quality control records were missing for six (6) consecutive days out of 12 days of operation in the month of January 2000. Also in the months of September, November 1999 and January 2000, your facility processed mammograms when the processor quality control records were missing in the range of 1 day to 6 days of operation. **21 CFR 900.12(e)(1)**

The specific deficiencies noted above appeared under the Level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. These deficiencies may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

In addition, your response should address the Level 2 noncompliance items that was listed on the inspection report provided to you at the close of the inspection. These Level 2 noncompliance items are:

1. Your records revealed that your facility did not document corrective actions for processor quality control failure on at least one occasion as required by **21 CFR 900.12(e)(8)(ii)**.
2. Your records revealed that no corrective action was taken when the processor density difference quality control test was out of limits on a day each of the months of May and October, 1999. **21 CFR 900.12(e)(8)(ii)(A)**.
3. Your records showed that no corrective actions were documented on June 8, 1999 for phantom images that failed to meet the required score and mammograms were performed on June 8 -11 and 16, 1999 without performing an additional phantom image quality control test. (**21 CFR 900.12(e)(2)(iii)**), as required by **21 CFR 900.12(e)(8)(ii)**.
4. Your facility did not have records for the weekly phantom tests for the weeks of December 26, 1999, January 2 and January 9, 2000, as required by (**21 CFR 900.12(e)(2)(iii)**), as required by **21 CFR 900.12(e)(8)(ii)**.
5. Your records did not demonstrate that up to the date of the inspection the radiologic technologist (██████████) meets the continuing education requirement of having fifteen hours of continuing education units in a 36-month period.

The other four items listed in your January 27, 2000 inspection report identified, as Level 3 should also be corrected. We will verify correction of these items during our next inspection. You are not required to address the Level 3 items in your written response.

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection identifies and promptly initiate permanent corrective actions.

If you fail to promptly correct these deficiencies, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

- Impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- Suspend or revoke a facility's FDA certificate for failure to comply with the Standards.
- Seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.

On February 17 and 18, 2000, this office received from your staff a packet of documents that addressed the Warning Letter, dated February 2, 2000 and by facsimile a set of continuing education documents of [REDACTED], respectively. We have reviewed your letters and attachments and evaluated the corrections made. Your letter and the facsimile indicated the corrections made are adequate and will be further verified in future inspection.

Please notify this office in writing within fifteen (15) working days of receipt of this letter if you performed any additional steps you may have taken in response to this amended Warning Letter.

If appropriate, please send the original copy of your response to:


R. Terry Bolen  
MQSA Compliance Officer  
Food and Drug Administration  
6751 Steger Dr.  
Cincinnati, OH 45237-3097

Also, as appropriate, please send a copy to the State radiation control office:

Mr. Dwight W. Leeseberg  
Ohio Department of Health  
Radiologic Technology Section  
161 S. High St., Suite 400  
Akron, OH 44308

If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call R. Terry Bolen at (513) 679-2700, extension 138.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Henry L. Fielden", with a stylized flourish at the end.

Henry L. Fielden  
District Director  
Cincinnati District Office

c.  
OH/DWLeeseberg

Director, Breast Imaging Accreditation Program  
American College of Radiology  
1891 Preston White Dr.  
Reston, VA 20191